Symptom Burden and Health Related Quality of Life of Cancer Patients With Concurrent Heart Failure

M.D. Anderson Cancer Center

Status

Enrolling

Conditions

Heart Failure

Study type

Observational

Funder types

Other

Identifiers

NCT06656715

2024-1125

Details and patient eligibility

About

To describe and compare the symptom burden in cancer patients with concurrent diagnosis of heart failure (HFrEF compared to HFpEF).

Full description

The investigators will conduct a symptom assessment at study enrollment on cancer participants with a concurrent diagnosis of HF (HFrEF and HFpEF) using the MD Anderson Symptom Inventory- Heart Failure (MDASI-HF) and PROMIS Instruments (Fatigue, Dyspnea, and Sleep Disturbance).

The investigators will also describe and compare the health-related quality of life using the European Organization for Research and Training Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the measure of Quality of Life Short Form-12 (SF-12).

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 years and older
Individuals with a concurrent solid tumor cancer diagnosis
Not receiving active cancer treatment except for those on maintenance (i.e., Selective ER modulators (SERMs)[Tamoxifen], Aromatase inhibitors (Anastrozole, Letrozole, Exemestane), Ovarian suppression therapy (GnRH Agonists [Leuprolide], Androgen deprivation therapy for prostate cancer
Completed cancer treatment at least 3 months and up to 3 years before study enrollment.

Therapy

Able to read, speak and consent in English
Ability to understand and the willingness to sign a written informed consent document
Diagnosis of heart failure, confirmed by echocardiogram, MUGA, or cardiac catheterization
Internet access via smart phone, tablet, a computer, or another device with the capacity to 1) download the Fitbit App and 2) complete electronic study assessments via REDCap.

Exclusion criteria